IP Library Granted Patent US 11,389,484
Granted Patent B2
US 11,389,484 · App. 16/214,485 · Granted Jul 19, 2022

Mesenchymal stem cells and uses therefor

Inventors: Sudeepta Aggarwal (North Potomac, MD); Mark F. Pittenger (Severna Park, MD); Timothy Varney (Baltimore, MD)
Assignee: Mesoblast International Sárl
A61K35/28A61K38/2026A61K38/2066A61K45/06A61P11/00C12N5/0662C12N5/0663C12N5/0664C12N5/0665C12N5/0666C12N5/0667C12N5/0668A61K2035/124Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,389,484
App. No.
16/214,485
Granted
Jul 19, 2022
Kind
B2
Abstract

Compositions and methods of promoting wound healing in a human by administering to the human mesenchymal stem cells in an effective amount.

Claims (19)

1. A method of treating an allergic disease or disorder in a human, said method comprising administering mesenchymal stem cells to the human in an amount effective to treat the allergic disease or disorder.

2. The method of claim 1 , wherein the mesenchymal stem cells are genetically unmanipulated.

3. The method of claim 1 , wherein the mesenchymal stem cells are allogeneic.

4. The method of claim 2 , wherein the mesenchymal stem cells are allogeneic.

5. The method of claim 1 , wherein the allergic disease or disorder is asthma, allergic rhinitis, atopic dermatitis, or contact dermatitis.

6. The method of claim 2 , wherein the allergic disease or disorder is asthma, allergic rhinitis, atopic dermatitis, or contact dermatitis.

7. The method of claim 3 , wherein the allergic disease or disorder is asthma, allergic rhinitis, atopic dermatitis, or contact dermatitis.

8. The method of claim 4 , wherein the allergic disease or disorder is asthma, allergic rhinitis, atopic dermatitis, or contact dermatitis.

9. The method of claim 1 , wherein the mesenchymal stem cells are administered systemically.

10. The method of claim 1 , wherein the mesenchymal stem cells are administered intravenously or intraarterially.

11. The method of claim 5 , wherein the mesenchymal stem cells are administered intravenously or intraarterially.

12. The method of claim 1 , wherein the mesenchymal stem cells are cultured.

13. The method of claim 5 , wherein the mesenchymal stem cells are cultured.

14. The method of claim 1 , wherein the mesenchymal stem cells are administered in an amount from about 1×10 5 cells/kg to about 1×10 7 cells/kg.

15. The method of claim 1 , wherein the mesenchymal stem cells are administered in an amount from about 1×10 6 cells/kg to about 5×10 6 cells/kg.

16. The method of claim 1 , wherein the mesenchymal stem cells were isolated from marrow.

17. The method of claim 16 , wherein the marrow is iliac crest marrow.

18. The method of claim 1 , wherein the mesenchymal stem cells were isolated from blood, skin, cord blood, muscle, fat, bone, or perichondrium.

19. A method of treating asthma in an human, said method comprising intravenously or intraarterially administering genetically unmanipulated allogeneic cultured mesenchymal stem cells to the human in an amount effective to treat the asthma.

Assignments (4)
RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jan 2, 2026
From: OAKTREE FUND ADMINISTRATION, LLC, AS AGENT
To: MESOBLAST LIMITED; MESOBLAST UK LIMITED; MESOBLAST, INC. (FORMERLY KNOWN AS ANGIOBLAST, INC.); MESOBLAST INTERNATIONAL SÀRL
Reel/Frame 074174/0183 →
SECURITY INTEREST Recorded Dec 10, 2021
From: MESOBLAST LIMITED ACN 109 431 870; MESOBLAST UK LIMITED; MESOBLAST, INC. (FORMERLY KNOWN AS ANGIOBLAST, INC.); MESOBLAST INTERNATIONAL SÀRL
To: OAKTREE FUND ADMINISTRATION, LLC
Reel/Frame 058957/0447 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 14, 2020
From: AGGARWAL, SUDEEPTA; PITTENGER, MARK F.; VARNEY, TIMOTHY
To: OSIRIS THERAPEUTICS, INC.
Reel/Frame 051824/0376 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 14, 2020
From: OSIRIS THERAPEUTICS, INC.
To: MESOBLAST INTERNATIONAL SARL
Reel/Frame 051824/0913 →
Cited By (4)
US 12,410,405 US 12,473,547 US 12,697,355 US 12,702,683